This can be understood by considering a similar scenario of the epidermal growth factor receptor gene (EGFR) mutated NSCLC treated by osimertinib relative to gefitinib/erlotinib in the front‐line setting.25 Given osimertinib is a highly active agent for the treatment of gefitinib/erlotinib‐resistant T790M tumor clone, the front‐line administration of osimertinib allows the early eradication of T790M part within an EGFR‐mutated tumor and thereby significantly improves tumor control relative to the front‐line use of gefitinib/erlotinib. The gene discussed is EGFR; the disease is neoplasm.